Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21365165 | 0.88 | STK17A (0.82) | STK17ASTK17B | |
| SCHEMBL20154845 | 0.88 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154742 | 0.88 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154805 | 0.85 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154747 | 0.85 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154730 | 0.85 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154751 | 0.83 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154833 | 0.82 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154801 | 0.82 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL20154815 | 0.82 | STK17A (1.00) | STK17ASTK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3539951-B1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2020-10-07 | — | — | EP | claimed |
| CN-110114344-B | Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory disease | 韩国化学研究院 | 2020-06-16 | — | — | CN | claimed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | claimed |
| EP-3539951-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | Korea Research Institute of Chemical Technology (KR) | 2019-09-18 | — | — | EP | claimed |
| EP-3539951-B1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3539951-B1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2020-10-07 | — | — | EP | disclosed |
| CN-110114344-B | Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory disease | 韩国化学研究院 | 2020-06-16 | — | — | CN | disclosed |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
| EP-3539951-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | Korea Research Institute of Chemical Technology (KR) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539951-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | Korea Research Institute of Chemical Technology (KR) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018088749-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | 한국화학연구원 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | DTYMK, TGFB1, DCK | STK17A 1127/4885STK17B 1114/4885 |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | TGFBR1, TGFBR2, TGFB1 | STK17A 885/4885STK17B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.